Transactions

BroadOak Partners and its bankers have built a successful track record of completing investment banking transactions in the life sciences industry

Date Client Transaction $(MM)
9/2011 Orion Genomics Non-exclusive license agreement with QIAGEN. N/A
9/2011 Cenetron BroadOak retained to provide ongoing financial advisory services. N/A
9/2010 SVT SVT gains exclusive rights in China to ENMD-2076 through an investment in EntreMed, Inc. $5
7/2010 Cayman Chemical Company Replacement and expansion of Cayman Chemical Company’s debt facilities. N/A
6/2010 Albany Molecular Research Acquisition of Hyaluron, Inc. $27
4/2010 Molecular Transfer Acquisition of GlobalStem, Inc. N/A
12/2009 Caliper Life Sciences Sale of in-vivo preclinical CRO services business to Taconic Farms, Inc. $11
10/2009 Alpha Innotech Sale of Alpha Innotech Corp. to Cell Biosciences, Inc. $20
10/2009 Clinical Data Collaboration and license agreement with Novartis N/A
8/2009 Clinical Data Sale of non-core assets to Intrexon Corporation N/A
3/2009 Assay Designs Sale of Assay Designs, Inc. to Enzo Biochem, Inc. $12
10/2008 Semrock Sale of Semrock Inc. to IDEX Corp. $60
4/2008 Martek Biosciences Acquisition of biodefense vaccines business from Avecia Biologics Limited $40
6/2007 Martek Biosciences Sale of Fluorescent Detection Products Business N/A
7/2006 In Vitro Technologies Sale of In Vitro Technologies, Inc to Celsis International Plc $30
3/2006 King Pharmaceuticals Acquisition of sales and marketing rights to EpiPen in Canada from Allerex Laboratory $25
12/2005 UpSivida Acquisition of Control Delivery Systems $104
10/2005 NovaScreen Sale of NovaScreen Biosciences to Caliper Life Sciences $22
10/2005 Alpha Innotech Merger with xtrana $20
7/2004 attobioscience Sale of high content screening instrumentation company to BD Biosciences $25
11/2001 Inverness Medical Technology Sale of publicly traded medical device company to Johnson & Johnson $1,300
7/2001 Bayer Sale of Sybron Biochemical Division to Novozymes N/A
5/2001 Somnus Sale of publicly traded medical device company to Gyrus Group $56
2/2001 MAP Sale of Munich based medical device company to ResMed $67
11/2000 RPI Implementation of Shareholders Rights Plan N/A
8/2000 Molecular Devices Acquisition of publicly traded drug discovery tools company LJL BioSystems $349